These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 19855396)

  • 1. Comprehensive characterization of cytochrome P450 isozyme selectivity across chemical libraries.
    Veith H; Southall N; Huang R; James T; Fayne D; Artemenko N; Shen M; Inglese J; Austin CP; Lloyd DG; Auld DS
    Nat Biotechnol; 2009 Nov; 27(11):1050-5. PubMed ID: 19855396
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Predictive models for cytochrome p450 isozymes based on quantitative high throughput screening data.
    Sun H; Veith H; Xia M; Austin CP; Huang R
    J Chem Inf Model; 2011 Oct; 51(10):2474-81. PubMed ID: 21905670
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Harnessing machine learning to predict cytochrome P450 inhibition through molecular properties.
    Zahid H; Tayara H; Chong KT
    Arch Toxicol; 2024 Aug; 98(8):2647-2658. PubMed ID: 38619593
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Insights into molecular basis of cytochrome p450 inhibitory promiscuity of compounds.
    Cheng F; Yu Y; Zhou Y; Shen Z; Xiao W; Liu G; Li W; Lee PW; Tang Y
    J Chem Inf Model; 2011 Oct; 51(10):2482-95. PubMed ID: 21875141
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hydroxylation and demethylation of the tricyclic antidepressant nortriptyline by cDNA-expressed human cytochrome P-450 isozymes.
    Olesen OV; Linnet K
    Drug Metab Dispos; 1997 Jun; 25(6):740-4. PubMed ID: 9193876
    [TBL] [Abstract][Full Text] [Related]  

  • 6. RS-Predictor models augmented with SMARTCyp reactivities: robust metabolic regioselectivity predictions for nine CYP isozymes.
    Zaretzki J; Rydberg P; Bergeron C; Bennett KP; Olsen L; Breneman CM
    J Chem Inf Model; 2012 Jun; 52(6):1637-59. PubMed ID: 22524152
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Kinetic characterization and identification of the enzymes responsible for the hepatic biotransformation of adinazolam and N-desmethyladinazolam in man.
    Venkatakrishnan K; von Moltke LL; Duan SX; Fleishaker JC; Shader RI; Greenblatt DJ
    J Pharm Pharmacol; 1998 Mar; 50(3):265-74. PubMed ID: 9600717
    [TBL] [Abstract][Full Text] [Related]  

  • 8. RS-WebPredictor: a server for predicting CYP-mediated sites of metabolism on drug-like molecules.
    Zaretzki J; Bergeron C; Huang TW; Rydberg P; Swamidass SJ; Breneman CM
    Bioinformatics; 2013 Feb; 29(4):497-8. PubMed ID: 23242264
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High-throughput cytochrome P450 (CYP) inhibition screening via a cassette probe-dosing strategy. VI. Simultaneous evaluation of inhibition potential of drugs on human hepatic isozymes CYP2A6, 3A4, 2C9, 2D6 and 2E1.
    Bu HZ; Magis L; Knuth K; Teitelbaum P
    Rapid Commun Mass Spectrom; 2001; 15(10):741-8. PubMed ID: 11344532
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Monitoring compound integrity with cytochrome P450 assays and qHTS.
    MacArthur R; Leister W; Veith H; Shinn P; Southall N; Austin CP; Inglese J; Auld DS
    J Biomol Screen; 2009 Jun; 14(5):538-46. PubMed ID: 19483146
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of obesity on the cytochrome P450 enzyme system.
    Kotlyar M; Carson SW
    Int J Clin Pharmacol Ther; 1999 Jan; 37(1):8-19. PubMed ID: 10027478
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CYPlebrity: Machine learning models for the prediction of inhibitors of cytochrome P450 enzymes.
    Plonka W; Stork C; Šícho M; Kirchmair J
    Bioorg Med Chem; 2021 Sep; 46():116388. PubMed ID: 34488021
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of the human cytochrome P450 isoforms mediating in vitro N-dealkylation of perphenazine.
    Olesen OV; Linnet K
    Br J Clin Pharmacol; 2000 Dec; 50(6):563-71. PubMed ID: 11136295
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Five distinct human cytochromes mediate amitriptyline N-demethylation in vitro: dominance of CYP 2C19 and 3A4.
    Venkatakrishnan K; Greenblatt DJ; von Moltke LL; Schmider J; Harmatz JS; Shader RI
    J Clin Pharmacol; 1998 Feb; 38(2):112-21. PubMed ID: 9549641
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Metabolism of the tricyclic antidepressant amitriptyline by cDNA-expressed human cytochrome P450 enzymes.
    Olesen OV; Linnet K
    Pharmacology; 1997 Nov; 55(5):235-43. PubMed ID: 9399333
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of the substrate specificities of human liver cytochrome P450s 2C9 and 2C18: application to the design of a specific substrate of CYP 2C18.
    Minoletti C; Dijols S; Dansette PM; Mansuy D
    Biochemistry; 1999 Jun; 38(24):7828-36. PubMed ID: 10387023
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oxidative metabolism of bunitrolol by complementary DNA-expressed human cytochrome P450 isozymes in a human hepatoma cell line (Hep G2) using recombinant vaccinia virus.
    Ono S; Tsutsui M; Gonzalez FJ; Satoh T; Masubuchi Y; Horie T; Suzuki T; Narimatsu S
    Pharmacogenetics; 1995 Apr; 5(2):97-102. PubMed ID: 7663534
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Luminogenic cytochrome P450 assays.
    Cali JJ; Ma D; Sobol M; Simpson DJ; Frackman S; Good TD; Daily WJ; Liu D
    Expert Opin Drug Metab Toxicol; 2006 Aug; 2(4):629-45. PubMed ID: 16859410
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The influence of ethnicity and antidepressant pharmacogenetics in the treatment of depression.
    Jann MW; Cohen LJ
    Drug Metabol Drug Interact; 2000; 16(1):39-67. PubMed ID: 10820582
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Transfer learning for cytochrome P450 isozyme selectivity prediction.
    Teramoto R; Kato T
    J Bioinform Comput Biol; 2011 Aug; 9(4):521-40. PubMed ID: 21776607
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.